Maria Papp1, Peter L Lakatos. 1. aDepartment of Gastroenterology, Institute of Medicine, University of Debrecen, Debrecen b1st Department of Medicine, Semmelweis University, Budapest, Hungary.
Abstract
PURPOSE OF REVIEW: Serum antibodies have the potential role to assist in the diagnosis, disease stratification and prognostication of inflammatory bowel disease (IBD). Understanding antibody formation might provide insight into the dysregulated immunological response to the gut microbiota in IBD. This review summarizes recent evidence regarding the role of serology in IBD. RECENT FINDINGS: There is accumulating evidence from cross-sectional and longitudinal studies and from recent meta-analyses that supports the value of serological markers in identifying patients with complicated disease phenotype and increased risk of surgery in patients with Crohn's disease. Anti-Saccharomyces cerevisiae antibody remains the most accurate single marker, and recently identified exocrine pancreas antibodies (GP2 and CUZD1) have been suggested as evidence for a role of antibodies in the pathogenesis of Crohn's disease. SUMMARY: Despite these various developments, the use of the serum antibodies remains complementary in clinical practice. New markers are being currently evaluated that may reflect events relevant to the pathogenesis of IBD.
PURPOSE OF REVIEW: Serum antibodies have the potential role to assist in the diagnosis, disease stratification and prognostication of inflammatory bowel disease (IBD). Understanding antibody formation might provide insight into the dysregulated immunological response to the gut microbiota in IBD. This review summarizes recent evidence regarding the role of serology in IBD. RECENT FINDINGS: There is accumulating evidence from cross-sectional and longitudinal studies and from recent meta-analyses that supports the value of serological markers in identifying patients with complicated disease phenotype and increased risk of surgery in patients with Crohn's disease. Anti-Saccharomyces cerevisiae antibody remains the most accurate single marker, and recently identified exocrine pancreas antibodies (GP2 and CUZD1) have been suggested as evidence for a role of antibodies in the pathogenesis of Crohn's disease. SUMMARY: Despite these various developments, the use of the serum antibodies remains complementary in clinical practice. New markers are being currently evaluated that may reflect events relevant to the pathogenesis of IBD.
Authors: Nora Sipeki; Laszlo Davida; Eszter Palyu; Istvan Altorjay; Jolan Harsfalvi; Peter Antal Szalmas; Zoltan Szabo; Gabor Veres; Zakera Shums; Gary L Norman; Peter L Lakatos; Maria Papp Journal: World J Gastroenterol Date: 2015-06-14 Impact factor: 5.742
Authors: Tamas Tornai; David Tornai; Nora Sipeki; Istvan Tornai; Rayan Alsulaimani; Kai Fechner; Dirk Roggenbuck; Gary L Norman; Gabor Veres; Gabriella Par; Alajos Par; Ferenc Szalay; Peter Laszlo Lakatos; Peter Antal-Szalmas; Maria Papp Journal: Sci Rep Date: 2018-01-10 Impact factor: 4.379
Authors: Gyorgy Kovacs; Nora Sipeki; Boglarka Suga; Tamas Tornai; Kai Fechner; Gary L Norman; Zakera Shums; Peter Antal-Szalmas; Maria Papp Journal: PLoS One Date: 2018-03-28 Impact factor: 3.240
Authors: Serena Longo; Marcello Chieppa; Luca G Cossa; Chiara C Spinelli; Marco Greco; Michele Maffia; Anna M Giudetti Journal: Proteomes Date: 2020-08-10